Kestra Private Wealth Services’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-49,600
Closed -$65.5K 1887
2026
Q1
$65.5K Sell
49,600
-1,600
-3% -$2.86K ﹤0.01% 1706
2025
Q4
$95.7K Buy
51,200
+1,300
+3% +$2.5K ﹤0.01% 1658
2025
Q3
$63.9K Buy
49,900
+22,000
+79% +$29.8K ﹤0.01% 1624
2025
Q2
$34.6K Buy
+27,900
New +$32.2K ﹤0.01% 1585

Other funds holding PACB

Kestra Private Wealth Services's PACB Position: Q2 2026 in Review

Kestra Private Wealth Services sold out of Pacific Biosciences (PACB) in Q2 2026, closing a stake of 49,600 shares — an estimated $65.5K sold.

Kestra Private Wealth Services first reported a position in PACB in Q2 2025 and held it in 4 quarters. The position peaked at $95.7K in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Kestra Private Wealth Services reported no remaining Pacific Biosciences position as of Q2 2026 after selling out during the quarter.
  • Kestra Private Wealth Services sold 49,600 Pacific Biosciences shares in Q2 2026, an estimated $65.5K.
  • Kestra Private Wealth Services first reported a position in Pacific Biosciences in Q2 2025 and held it in 4 quarters.
  • Kestra Private Wealth Services's Pacific Biosciences position peaked at $95.7K in Q4 2025.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Kestra Private Wealth Services's 13F filing for Q2 2026, filed 28 Jul 2026.